Program
KH607
A development code. Also written as “KH607 tablets”, “Part B: KH607” and “KH607 tablet”.
Its studies are mostly in Depressive Disorder, Major, led by Chengdu Kanghong Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Kanghong Pharmaceutical Group | 64 open or running | phase 3since Jul 23, 2026 | Jan 4, 2024 | Dec 2027phase 3 · NCT07741331 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 4, 2024First study: phase 1 study in HealthyFirst studyNCT06393803 · 88 planned · China
- Jul 24, 20252 phase 2 studiesNCT07101120, NCT07096791
- May 27, 2026Phase 1 study in Food Effect of KH607 in Chinese Health ParticipantsNCT07634874 · 16 planned
- Jul 23, 20262 phase 3 studies in Depressive Disorder, MajorPhase 3 reachedNCT07741331, NCT07741240
Ahead
- Dec 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07741331
- Dec 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07741240
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07741331Depressive Disorder, Major | 3 | Not yet recruiting | Dec 2027 | 326 |
| NCT07741240Depressive Disorder, Major | 3 | Not yet recruiting | Dec 2027 | 232 |
| NCT07634874Food Effect of KH607 in Chinese Health Participants | 1 | Not yet recruiting | Jul 2026 | 16 |
| NCT07101120Depressive Disorder, Major · China | 2 | Completed | Feb 9, 2026 | 126 |
| NCT07096791Postpartum Depressive Disorder · China | 2 | Completed | Apr 24, 2026 | 72 |
| NCT06393803Healthy · China | 1 | Recruiting | Oct 30, 2024 | 88 |
How it is read
Names in the registry
- “KH607 tablets”, 6 entries
- “KH607”, 2 entries
- “Part B: KH607”, 1 entry
- “KH607 tablet”, 1 entry
- “2mg KH607 tablets”, 1 entry
Codes read as this program: KH607.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.